Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Morgan Stanley analyst Terence Flynn has maintained their bearish stance on BMY stock, giving a Sell rating on September 3. Terence Flynn has ...

Delayed diagnosis and treatment of CCCA result in insufficiently aggressive therapy and risks an avoidable consequence, ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage the loss of exclusivity now that some of its top-selling drugs are facing competition from generics. Disappointing results from the ...

Bristol Myers Squibb (NYSE: BMY) has struggled to manage ... with a portfolio of more than 30 products and an even larger clinical pipeline across fields like hematology, oncology, cardiology ...

This could be one of the largest products potentially in the Bristol-Myers Squibb portfolio. Milvexine, we're incredibly excited about. We're now the only -- could be the only player in atrial ...

Several pipeline products in phase 3 trials ... My interpretation is that Bristol Myers Squibb is fundamentally undervalued, with room for that spread to converge higher toward the group.

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...